Bronconex Acticap

Land: Nieuw-Zeeland

Taal: Engels

Bron: Medsafe (Medicines Safety Authority)

Werkstoffen:

Mometasone furoate 400ug (anhydrous)

Beschikbaar vanaf:

Organon (New Zealand) Limited

INN (Algemene Internationale Benaming):

Mometasone furoate 400 µg (anhydrous)

Dosering:

400 mcg/dose

farmaceutische vorm:

Powder for inhalation

Samenstelling:

Active: Mometasone furoate 400ug (anhydrous) Excipient: Lactose

Eenheden in pakket:

Inhaler, metered, DPI, (sample), 14 dose units

klasse:

Prescription

Prescription-type:

Prescription

Geproduceerd door:

MSD International GmbH (Singapore Branch)

therapeutische indicaties:

Bronconex Acticap is indicated for prophylactic therapy in the management of patients with asthma of all severities, including patients who have been dependent upon either inhaled or systemically administered corticosteroids and non-corticosteroid-dependent patients inadequately controlled on other drug regimens.

Product samenvatting:

Package - Contents - Shelf Life: Inhaler, metered, DPI, (sample) - 14 dose units - 18 months from date of manufacture stored at or below 25°C - Inhaler, metered, DPI - 30 dose units - 18 months from date of manufacture stored at or below 25°C - Inhaler, metered, DPI - 60 dose units - 18 months from date of manufacture stored at or below 25°C

Autorisatie datum:

2000-12-05